Review of drug interactions with telaprevir and antiretrovirals

被引：30

作者：

van Heeswijk, Rolf P. G. ^{[1
]}

Beumont, Maria ^{[1
]}

Kauffman, Robert S. ^{[2
]}

Garg, Varun ^{[2
]}

机构：

[1] Janssen Infect Dis BVBA, Beerse, Belgium

[2] Vertex Pharmaceut Inc, Cambridge, MA USA

来源：

ANTIVIRAL THERAPY | 2013年 / 18卷 / 04期

关键词：

HEPATITIS-C VIRUS; HIV-INFECTION; PHARMACOKINETICS; GLYCOPROTEIN; PROTEASE; EPIDEMIOLOGY; COINFECTION; INHIBITOR; THERAPIES; TENOFOVIR;

D O I：

10.3851/IMP2527

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

HCV infection is a major cause of mortality worldwide. HCV-related deaths also represent a leading cause of mortality in HIV-coinfected individuals. Telaprevir is an NS3/4A protease inhibitor approved for the treatment of chronic HCV genotype 1 infection in adults in combination with pegylated interferon and ribavirin. Telaprevir-based treatment has been shown to increase rates of sustained viral response in HCV genotype-1-monoinfected patients, and studies in HCV-HIV-coinfected patients are ongoing. Drug-drug interactions of telaprevir with antiretroviral drugs were investigated in a series of studies in healthy subjects. This review summarizes the results of interaction studies with low-dose ritonavir, ritonavir-boosted HIV protease inhibitors (atazanavir, darunavir, fosamprenavir and lopinavir), efavirenz, etravirine, rilpivirine, tenofovir disoproxil fumarate and raltegravir.

引用

页码：553 / 560

页数：8

共 39 条

[1] Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].